Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 7/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29424266 | 1.00 | HTR4 (0.65) | HTR4 | |
| SCHEMBL29889091 | 1.00 | HTR4 (0.65) | HTR4 | |
| SCHEMBL1802246 | 1.00 | HTR4 (0.65) | HTR4 | |
| Hydrochloric Acid SCHEMBL7309004 | 0.99 | HTR4 (0.64) | HTR4 | |
| SCHEMBL4543915 | 0.91 | HTR4 (0.67) | HTR4 | |
| Dazopride SCHEMBL184075 | 0.83 | HTR4 (0.72) | HTR4 | |
| Dazopride SCHEMBL7339808 | 0.82 | HTR4 (0.71) | HTR4 | |
| SCHEMBL5077815 | 0.82 | DRD2 (0.43) | HTR4 | |
| SCHEMBL2522742 | 0.81 | DRD4 (0.58) | HTR4 | |
| Hydrochloric Acid SCHEMBL7309340 | 0.81 | DRD4 (0.57) | HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002036113-A1 | COMPOSITION COMPRISING: SEROTONIN RECEPTOR ANTAGONISTS (5HT-2, 5HT-3) AND AGONIST (5HT-4) | RESPIRATORIUS AB (SE) | 2002-05-10 | — | — | WO | claimed |
| WO-2001095902-A1 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | claimed |
| JP-8291140-A | — | — | None | — | — | JP | disclosed |
| JP-9249561-A | — | — | None | — | — | JP | disclosed |
| EP-4706758-A2 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20240325487-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2024-10-03 | — | — | US | disclosed |
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-3884935-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-114404588-A | Compounds and methods for inhibiting phosphate transport | 阿德利克斯公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3972599-A1 | COMBINATION FOR LOWERING SERUM PHOSPHATE IN A PATIENT | Ardelyx, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| CN-105979959-B | Compounds and methods for inhibiting phosphate transport | 阿德利克斯公司 | 2021-11-30 | — | — | CN | disclosed |
| WO-2002036113-A1 | COMPOSITION COMPRISING: SEROTONIN RECEPTOR ANTAGONISTS (5HT-2, 5HT-3) AND AGONIST (5HT-4) | RESPIRATORIUS AB (SE) | 2002-05-10 | — | — | WO | disclosed |
| WO-2001095902-A1 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | disclosed |
| EP-0880502-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1998-12-02 | — | — | EP | disclosed |
| JP-H09249561-A | DRUG COMPOSITION | TEIKOKU CHEM IND CORP LTD | 1997-09-22 | — | — | JP | disclosed |
| WO-1997028129-A1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LIMITED (GB) | 1997-08-07 | — | — | WO | disclosed |
| EP-0481756-B1 | Benzamide derivatives | TEIKOKU CHEM IND CO LTD (JP) | 1997-07-09 | — | — | EP | disclosed |
| JP-H08291140-A | EASILY ABSORBABLE CRYSTAL | TEIKOKU CHEM IND CORP LTD | 1996-11-05 | — | — | JP | disclosed |
| US-5143935-A | Gastrointestinal disorders | TEIKOKU CHEMICAL INDUSTRY CO., LTD. (JP) | 1992-09-01 | — | — | US | disclosed |
| EP-0481756-A2 | Benzamide derivatives | TEIKOKU CHEMICAL INDUSTRY CO., LTD. (JP) | 1992-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325487-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | HTR4 1928/4885 |
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | SLC34A3, SLC34A2, SLC34A1 | HTR4 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.